Dr. Kafrissen is currently the Chief Executive Officer of STE Health International, LLC. He also currently serves as Director of Research and Innovation for the World Health Organization Collaboration Center at UNC-Chapel Hill. He was previously Company Head and Chief Scientific Officer of Ortho-McNeil Janssen Scientific Affairs, LLC, and a member of the Johnson & Johnson’s North American Pharmaceutical Management board. His responsibilities comprise J&J companies focusing on neurology, psychiatry, analgesia, anti-infectives, gastroenterology, women’s health, urology, pediatrics, and cardiovascular diseases. He serves on the Board of Directors of the American Foundation for Pharmaceutical Education and is a member of the Centers for Disease Control Foundation’s Corporate Roundtable.
His academic appointments include Adjunct Professorships at the University of North Carolina at Chapel Hill, School of Public Health, Rutgers University School of Pharmacy, and University of Pennsylvania, School of Medicine.
Prior to joining Johnson & Johnson, Dr. Kafrissen was a Medical Epidemiologist in the Centers for Disease Control’s Chronic Disease Division in Atlanta, GA engaging in research ranging from pregnancy-related mortality to Vietnam combat. His initial role at J&J was in pharmaceutical development where his groups were responsible for a number of novel product approvals.
Dr. Kafrissen’s research interests include geriatrics/gerontology, pharmacoepidemiology, clinical trial design, clinical project planning and execution, and management of technical professionals. He is the author of numerous articles, book chapters, and originator of clinically-related patents.
